Stay abreast of COVID-19 information and developments here
Provided by the South African National Department of Health
what changes will the presidential election bring?
Senior Equity Analyst
Sep 13, 2016
The healthcare services market in the US has historically been expensive and deeply flawed, with 8% of Americans still not able to afford healthcare insurance. President Barack Obama attempted a radical overhaul with his controversial Affordable Care Act (ACA or Obamacare), which sought to expand the coverage of health insurance and increase health insurance quality and affordability. However, the implementation of Obamacare has been plagued with challenges, and both 2016 US presidential candidates are likely to propose fundamental changes. Still, it may prove even more challenging to get these passed through the House of Representatives and the Senate.
As the Sanlam Private Wealth (SPW) global equity team, we view healthcare as an appealing sector and are already invested through Roche and Medtronic, among other stocks. So we have a keen interest in how a Clinton versus Trump win could impact the US healthcare industry. Hillary Clinton broadly supports ACA, and if she wins, is likely to strengthen the current legislation. Donald Trump, on the other hand, will go to the other extreme, attempting to dismantle ACA as it exists today and completely overhauling it if possible. So the party that will gain control of the White House, Senate and House of Representatives will be the single most important element in predicting the outcome for ACA. But with neither likely to take out-and-out control, it’s probable that no significant reform will happen in the foreseeable future.
Having said this, it does look like there will be some significant changes to Obamacare over the longer term. There could be implications for pharmaceutical stocks as pricing comes under scrutiny. Within the pharmaceutical sector in particular, we favour biopharmaceutical businesses that have portfolios and pipelines for therapies targeting unmet patient needs and serious illnesses. Roche is an example of one such stock that we hold. Driven by its hugely successful and clinically effective blockbuster drugs – Avastin, Rituxan and Herceptin – Roche has become a global leader in oncology therapies.
We also believe the need for efficiencies to improve the quality of care will accelerate the adoption of new and innovative technologies. Medtronic, which we bought in 2015 and which has outperformed the market by 16% in US dollar terms, has been an excellent addition to our portfolio. The company places an emphasis on strategic customer relationship and shared accountability for outcomes, enabling it to provide cost benefit solutions to healthcare providers. Overall, we see minimal impact on medical devices from any government initiatives.
It’s an interesting time in US history and the healthcare industry is right at the heart of many fundamental policy talks and campaign promises. We believe this is a good time to consider some long-term investment opportunities in certain well-considered stocks in the US healthcare system.
Sanlam Private Wealth manages a comprehensive range of multi-asset (balanced) and equity portfolios across different risk categories.
Our team of world-class professionals can design a personalised offshore investment strategy to help diversify your portfolio.
Our customised Shariah portfolios combine our investment expertise with the wisdom of an independent Shariah board comprising senior Ulama.
We collaborate with third-party providers to offer collective investments, private equity, hedge funds and structured products.
navigating the complexities
Sanlam Trustees International
are they a good investment?
The great lockdown:
one year on
Head of Equities
IHG: focus on
quality pays off
Sanlam Active UK Fund
BUDGET 2021: THE RIGHT INTENT,
BUT RISKS ABOUND
Investment Economist at Sanlam Investments
INVESTING IN 2021:
WHAT TO EXPECT
Sanlam Private Wealth
MINING: IS THE
THROUGH THE HYPE
Head of Equities
South AfricaSouth Africa Home Sanlam Investments Sanlam Private Wealth Glacier by Sanlam Sanlam BlueStar
Rest of AfricaSanlam Namibia Sanlam Mozambique Sanlam Tanzania Sanlam Uganda Sanlam Swaziland Sanlam Kenya Sanlam Zambia Sanlam Private Wealth Mauritius
GlobalGlobal Investment Solutions
Sanlam Private Wealth (Pty) Ltd, registration number 2000/023234/07, is a licensed Financial Services Provider (FSP 37473), a registered Credit Provider (NCRCP1867) and a member of the Johannesburg Stock Exchange (‘SPW’).
All reasonable steps have been taken to ensure that the information on this website is accurate. The information does not constitute financial advice as contemplated in terms of FAIS. Professional financial advice should always be sought before making an investment decision.
Participation in Sanlam Private Wealth Portfolios is a medium to long-term investment. The value of portfolios is subject to fluctuation and past performance is not a guide to future performance. Calculations are based on a lump sum investment with gross income reinvested on the ex-dividend date. The net of fee calculation assumes a 1.15% annual management charge and total trading costs of 1% (both inclusive of VAT) on the actual portfolio turnover. Actual investment performance will differ based on the fees applicable, the actual investment date and the date of reinvestment of income. A schedule of fees and maximum commissions is available upon request.
COLLECTIVE INVESTMENT SCHEMES
The Sanlam Group is a full member of the Association for Savings and Investment SA. Collective investment schemes are generally medium to long-term investments. Past performance is not a guide to future performance, and the value of investments / units / unit trusts may go down as well as up. A schedule of fees and charges and maximum commissions is available on request from the manager, Sanlam Collective Investments (RF) Pty Ltd, a registered and approved manager in collective investment schemes in securities (‘Manager’).
Collective investments are traded at ruling prices and can engage in borrowing and scrip lending. The manager does not provide any guarantee either with respect to the capital or the return of a portfolio. Collective investments are calculated on a net asset value basis, which is the total market value of all assets in a portfolio including any income accruals and less any deductible expenses such as audit fees, brokerage and service fees. Actual investment performance of a portfolio and an investor will differ depending on the initial fees applicable, the actual investment date, date of reinvestment of income and dividend withholding tax. Forward pricing is used.
The performance of portfolios depend on the underlying assets and variable market factors. Performance is based on NAV to NAV calculations with income reinvestments done on the ex-dividend date. Portfolios may invest in other unit trusts which levy their own fees and may result is a higher fee structure for Sanlam Private Wealth’s portfolios.
All portfolio options presented are approved collective investment schemes in terms of Collective Investment Schemes Control Act, No. 45 of 2002. Funds may from time to time invest in foreign countries and may have risks regarding liquidity, the repatriation of funds, political and macroeconomic situations, foreign exchange, tax, settlement, and the availability of information. The manager may close any portfolio to new investors in order to ensure efficient management according to applicable mandates.
The management of portfolios may be outsourced to financial services providers authorised in terms of FAIS.
TREATING CUSTOMERS FAIRLY (TCF)
As a business, Sanlam Private Wealth is committed to the principles of TCF, practicing a specific business philosophy that is based on client-centricity and treating customers fairly. Clients can be confident that TCF is central to what Sanlam Private Wealth does and can be reassured that Sanlam Private Wealth has a holistic wealth management product offering that is tailored to clients’ needs, and service that is of a professional standard.